Cellmid is an Australian Life Sciences accelerator with lead programs in multiple disease indications
The Company, through its wholly owned subsidiaries
Lyramid, Kinera, and Advangen, develops and markets innovative novel therapies
and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic
diseases of the heart, and hair loss. Cellmid holds the largest and most
comprehensive portfolio of intellectual property relating to the novel targets
midkine (MK) and FGF5 globally.
Through its Advangen business, Cellmid sells
its FGF5 inhibitor hair growth products in Australia and Japan, and is
expanding distribution in other territories.
For further information, please see www.evolisproducts.com.au.